

Commonwealth of Massachusetts

MassHealth Drug Utilization Review Program

P.O. Box 2586

Worcester, MA 01613-2586

First name

**Fax:** 1-877-208-7428 **Phone:** 1-800-745-7318

## **Narcotic Prior Authorization Request**

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

PA is required for quantity requests greater than 30 patches/month for Duragesic and/or 90 tablets/month for OxyContin. PA is also required for dosages that exceed 200 mcg/hour for Duragesic and/or 240 mg/day for OxyContin.

MI

Effective May 1, 2004, hydromorphone powder, levorphanol powder, and oxycodone powder will require PA. Effective June 1, 2004, Duragesic and OxyContin will require PA. Additional information about which drugs require PA can be found within the MassHealth Drug List at **www.mass.gov/masshealth**.

MassHealth member ID no.

Date of birth | Sex (Circle one.)

## **Member information**

Last name

Member's place of residence ☐ home	nursing facility			
Medication information				
Section I Narcotic request Strength Quantity (Complete a separate line for each strength prescribed.)	Dose, frequency, and duration of requested drug	Drug NDC (if known) or service code		
	Indication (Check one or all that apply.)			
☐ Duragesic (fentanyl)	☐ Cancer pain (specify type and stage):			
☐ Duragesic (fentanyl)				
OxyContin (oxycodone)	Please specify: Active treatment Palliati	ve care		
OxyContin (oxycodone)				
Other:				
	Has member tried sustained-release morphine or methadone?			
Please complete for all narcotic PA requests.	Yes. Complete box below. No. Explain why not.			
	Drug name			
	Dates of use Dose and fre	equency		
	Did member experience any of the following?			
	☐ Adverse reaction ☐ Inadequate response ☐ Other			
	Details of adverse reaction, inadequate response, or other:			
	How is the member's response to treatment being measuractivity level)?	sured (e.g., pain-assessment scales,		

PA-12 (Rev. 04/04) over ▶

## **Medication information** (cont.)

Section II	ls t	the member under the care	of a pain specialist?	Yes	□No			
Please complete if the request is for Duragesic at doses > 200 mcg/hour, for OxyContin at doses > 240 mg/day, or for compounds.	Na	Name of specialist:			Phone no.: ()			
	Da	Date of last visit or consult with pain specialist:						
	What is the complete pain-management regimen, including other pain medications, adjunctive therapy, and/or controlled substances? Please include the names and doses of these medications.							
	Ha	Has the member had a psychological evaluation?			□No			
	Do	Does the member: have a history of substance abuse or dependence? have a history of alcohol abuse or dependence?			□ No			
	Does the member have a treatment agreement (e.g., lock-in pharmacy and prescriber, early refill policy, consequences of nonadherence to treatment)?							
		☐ Yes (Attach copies.) ☐ No (Explain why not.)						
	-							
Pharmacy information								
Name		Pharmacy provider no.	Telephone no.	Fax no	).			
Address			City	State	Zip			
Prescriber information								
Last name First na	st name First name MI			. DEA no	DEA no.			
Address			City	State	Zip			
E-mail address			Telephone no.	Fax no	)			
Signature								
l certify that the information provided is falsification, omission, or concealment o					derstand that an			
Prescriber's signature (Stamp not accept		Date						